Get started

Biotech

MVMD — Target of shoddy short hit piece by anonymous SA authorThis is a very similar setup to my earlier EXRO call where an anonymous author calling him/herself “Mariner Research Group” put together a shoddy “short thesis” that was quite frankly garbage. It would not surprise me if this “Night Research Group” is the exact same person. Same quality of work, same hastily put together WordPress website with no contact info other than email and no names of who is behind it. Same terrible track record where none of the previous price targets have been reached. Same low follower count. From the technical perspective, MVMD is oversold on the hourly and is approaching oversold territory on the daily chart . .95 gap was filled and support was found at the .96 Fibonacci line. If support holds, it will start forming a bullish Double Bottom pattern. There’s also a gap at 1.10 up above. Decent risk/reward but stop loss is not a bad idea, IMO.
CSE:MVMDLong
by wealth_bakery
HGEN: Weekend Before Phase III DataHGEN has two RCTs with imminent data, one of them the company's own, the other the NIH's ACTIV-5 Trial. The company is preparing to file an EUA for Lenzilumab pending the trials' completion. Announcements are expected in the week starting March 29, two days from now. Nomis Bay, a fund that had held a large stake of HGEN since it was trading in single digits unloaded millions of shares in the weeks leading up to now. The fund still holds between 9% and 10% of the outstanding shares.In conferences throughout March, HGEN executives mainly showcased the potential for Lenz as a COVID therapeutic, and differences between their trial designs and those of other, failed monoclonal antibodies. I hope everyone is sized appropriately, whether long or short. This stock could make some very large moves soon.
HLong
by decaro
$APOP and Quoin Pharmaceuticals Announce Strategic MergerCellect Biotechnology and Quoin Pharmaceuticals Announce Strategic Merger Up to $25 million of funding at $75 million pre-money valuation to be available to the combined company concurrently with the merger Cellect shareholders to retain 25% of the combined Company pre-funding Quoin has secured $25 million in committed equity funding from Altium Capital, a highly regarded institutional healthcare investor. Quoin has also negotiated an $18.5 million venture loan from a leading U.S. commercial bank. Completion of the merger is subject to approval of the Cellect and Quoin shareholders and certain other conditions and is expected to close by the end of the second quarter of 2021.
A
by AlenCiken
Why $IMMP soared in December case studyFirst time an antigen presenting cell (APC) activator has shown an Overall Survival (OS) benefit in a randomised setting in metastatic breast cancer patients known to be insensitive to immune checkpoint inhibitor therapy Promising and improving overall trend in OS in total population (based on approx. 60% of events): median survival benefit of +2.7 months from efti plus chemotherapy, compared to chemotherapy plus placebo. Statistically significant OS benefit in efti group observed in pre-defined patient groups: +7.1 months survival benefit (median of 21.9 vs. 14.8 months, nearly 50% longer) from efti with chemotherapy for patients under 65 years of age +9.4 months survival benefit (median of 22.4 vs. 12.9 months, 74% longer) from efti with chemotherapy for patients with a low starting monocyte count Statistically significant increase in CD8 T cells in patients treated with efti plus chemotherapy, correlated with prolonged OS, indicating pharmacodynamic activity and proof of concept of efti’s mode of action Collection of OS data ongoing, with final data expected to be reported mid 2021 finance.yahoo.com
NASDAQ:IMMP
by AlenCiken
$PRQR Announces Positive Results from Clinical Trial of QR-421aProQR Announces Positive Results from Clinical Trial of QR-421a in Usher Syndrome and Plans to Start Pivotal Trials. QR-421a demonstrated a concordant benefit in multiple measures of vision, including best corrected visual activity (BCVA), static perimetry, and retinal imaging (OCT) QR-421a observed to be well tolerated with no serious adverse events reported Two pivotal Phase 2/3 trials are expected to start by the end of 2021 finance.yahoo.com
NASDAQ:PRQR
by AlenCiken
APOP Cellect Biotechnology Upside PotentialNext time when you see those upside spikes is a chart, that is and extremely bullish sign. Maybe some insider buys! Cellect Biotechnology Ltd. (NASDAQ: APOP), a developer of innovative technology that enables the functional selection of stem cells, and Quoin Pharmaceuticals Inc. (“Quoin”), a privately held specialty pharmaceutical company, today announced that the Boards of Directors of the two companies have unanimously approved a definitive Merger Agreement. (globenewswire.com) Market Cap of only 13.644M. This still has room to grow! If you are interested to test some amazing BUY and SELL INDICATORS which give the signal at the beginning of the candle, not at the end of it, just leave me a message.
ALong
by TopgOptions
2
$bntc Skyrocket as Morgan Stanley Takes StakeBenitec Shares Skyrocket as Morgan Stanley Takes Stake $BNTC shares blasted higher Tuesday after disclosing in a regulatory filing that Morgan Stanley has a 5.2% stake in the genetic drug company. The stake amounts to 249,174 shares, or about $1.51 million. Benitec‘s “proprietary platform, called DNA-directed RNA interference, or ddRNAi, combines RNA interference, or RNAi, with gene therapy to create medicines that facilitate sustained silencing of disease-causing genes following a single administration,” the company said. “The company is developing ddRNAi-based therapeutics for chronic and life-threatening human conditions including Oculopharyngeal Muscular Dystrophy (OPMD), and Chronic Hepatitis B.” www.thestreet.com
NASDAQ:BNTC
by AlenCiken
BNTC Benitech Biopharma we bought the dipMorgan Stanley disclosed in an SEC filing that it had increased its stake in the company by around 5.2%! Don`t worry, it has still upside potential, despite the 130% increase in the Pre-Market. Market Cap of only 15.37M This is a 5X stock, Not trading advice as you know! :) This was a private call from my trading group and one of my top picks for March. You can check the transcripts here: www.patreon.com If you are also interested to test some amazing BUY and SELL INDICATORS that i use, which give the signal at the beginning of the candle, not at the end of it, just leave me a message.
NASDAQ:BNTCLong
by TopgOptions
16
SNCA has broken out of a descending channel Catalyst Seneca Biopharma, Inc. (Nasdaq: SNCA) entered into a agreement with a privately held company Leading BioSciences, Inc. (“LBS” for a merger with to form Palisade Bio, Inc. SNCA has broken out of a descending channel and retested the upper trend line. The idea is self explanatory targets and stop loss is marked on the chart. A good risk management is key to success in the financial markets. Risk only a small portion of your portfolio in this risky but potential trade.
SLong
by ascendanto
Is This Volume Any Indicator Of A New Trend?MRKR has been a sleeper all year. No major high-volume days and nothing really to write home about. But it managed to pull off a bigger move earlier on. Now that the gap has filled from the drop a few weeks ago & they secured funds, what will this mean for the company's next steps? "An onslaught of Form 4s showed hand fulls of investors and insiders participating in the recent offering. The company raised the money to fund its Phase 2 trial of MT-401 in acute myeloid leukemia. Marker also plans to develop MultiTAA therapies into clinical trials in other indications and conduct manufacturing activities, among other things. In addition to this, analysts have also weighed in recently. Cantor Fitzgerald initiated coverage on Marker this month. The firm started MRKR at Overweight and gave a price target of $6." Quote Source: Best Penny Stocks On Robinhood To Watch This Week If You Like Biotech
NASDAQ:MRKR
by PennyStocks101
Back In The Channel AgainMNKD is back in that Fib channel between the .5 and .382 levels. This was a previous channel earlier in the year. Now that the financing deal is done, will it finally see a prolonged uptrend without much interruption? " However, with fresh capital in hand, the company aims at advancing its current pipeline. This includes a Phase 3 clinical trial of its Afrezza inhaled insulin product in pediatric subjects. MannKind also explained that it wants to further the development of product candidates in its pipeline. The company may also use a portion of the proceeds for acquisitions or strategic investments in complementary businesses or technologies. Even with the pullback, analysts seem to remain bullish on the company. SVB Leerink most recently adjusted its price target on the stock. It had previously issued a $3 target but upped it to $5. The firm also carries an Outperform rating on the stock. " Quote Source: Best Penny Stocks On Robinhood To Watch This Week If You Like Biotech
NASDAQ:MNKD
by PennyStocks101
SELB Back In High TrafficSELB is back in the upper area of its high-traffic support/resistance from several times prior. Most recently, it saw this act as support in February. But it wasn't able to sustain the level. Anyway, it's back at this but in this case, the level has acted as a potential resistance (for now). It's gonna be interesting to see what happens next. Selecta seems to have benefited from a bullish outlook discussed by the company in its last corporate update. “We are very pleased by the continued progress of our gene therapy program. In collaboration with AskBio, our lead program in methylmalonic acidemia, is on track to enter the clinic in the second quarter of this year, and we expect initial data by the end of the year,” said Carsten Brunn, Ph.D., president, and chief executive officer of Selecta. “A key objective of 2021 will be to generate human data in our gene therapy programs and to continue to build our extensive pipeline in gene therapies, enzyme therapies–with an expected IND filing by the end of the year in IgA nephropathy–and autoimmune diseases, as we work to deliver on our mission to leverage our pioneering ImmTOR platform to improve the lives of patients and their families.” Quote Source: Best Penny Stocks On Robinhood To Watch This Week If You Like Biotech
S
by PennyStocks101
Is OPK Fibbin'?OPK back at the .236 fib line, which has been a clear area of support/resistance. The question is, will the speculation on its testing company end up giving the boost needed to push back above the $5 mark or is this truly a "fib" and OPK falls back down heading into the rest of March? "Ongoing pressure from an activist investor to offload its BioReference unit has also become a source of speculation. This stemmed from recent M&A action within the diagnostics space earlier this month. Needless to say, the recent action in the stock has continued supporting some analysts’ bullish stances on the company. Most recently, Barrington Research boosted its price target to $8 from $7 and maintained its Outperform rating." Quote Source: Best Penny Stocks On Robinhood To Watch This Week If You Like Biotech
NASDAQ:OPK
by PennyStocks101
Rubraca® Significantly Improves Progression-Free SurvivalClovis Oncology’s Rubraca® (rucaparib) Significantly Improves Progression-Free Survival versus Chemotherapy in Patients with Later-line Ovarian Cancer Associated with a BRCA Mutation The ARIEL4 study met its primary endpoint, showing a statistically significant improvement in investigator-assessed progression-free survival (PFS) for Rubraca versus chemotherapy The safety of Rubraca observed in the ARIEL4 study was highly consistent with both the U.S. and EU product labels.
C
by AlenCiken